GLP1R and polycystic ovary syndrome: However, as opposed to the long-acting GLP1 analog, liraglutide, used in our study, they used short-acting GLP-1 analog, exenatide, in treatment-naive overweight patients (BMI >27 kg/m2) with PCOS for 24 weeks (11).